Company news
aTyr Pharma, Inc. news in 2024
aTyr Pharma, Inc.'s news releases, calls and decks from 2024, newest first.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
December 11, 2024
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
December 9, 2024
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
December 8, 2024
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 14, 2024
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 6, 2024
aTyr Pharma to Present at the LD Micro Main Event XVII in October
October 13, 2024
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 7, 2024
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 1, 2024
aTyr Pharma to Participate in September Investor Conferences
August 20, 2024
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 12, 2024
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
August 5, 2024
aTyr Pharma Announces Research Study with Stanford Medicine
July 29, 2024
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 21, 2024
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 2, 2024
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14, 2024
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 13, 2024
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 1, 2024
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 13, 2024
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 27, 2024
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 20, 2024
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 28, 2024
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 17, 2024